Current with changes from the 2024 Legislative Session
Section 13-3502 - Establishment of guidelines for co-providing opioid overdose reversal drugs(a) The Secretary shall establish guidelines for the co-prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21-2A-01 of this article.(b) The guidelines established under subsection (a) of this section shall address the co-prescribing of opioid overdose reversal drugs for patients who are: (1) At an elevated risk of overdose; and(2)(i) Receiving opioid therapy for chronic pain;(ii) Receiving a prescription for benzodiazepines; or(iii) Being treated for opioid use disorders.Added by 2017 Md. Laws, Ch. 572,Sec. 1, eff. 6/1/2017.Added by 2017 Md. Laws, Ch. 571,Sec. 1, eff. 6/1/2017.